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Oral Pre-anaesthetic Medication with a
New Benzodiazepine Hypnotic
S. A. HARE, M.B. CH.B. UNIY. PRET., D.A. UNIY. RAJ'm, Specialist Anaesthetist, Johannesburg
SUMMARY
A new benzodiazepine derivative (Ro 5-4200) was used
as a hypnotic in a pilot study on 30 patients the night
before an operation. The dosage used was 2 mg (1
tablet). Results proved very encouraging, and it was then
decided to conduct a controlled double-blind trial com-
paring Ro 5-4200, phenobarbital 100 mg and a placebo
In 150 patients (50 patients each way). At a dosage of 2
mg Ro 5-4200 produced significantly better results than
phenobarbital and the placebo as an oral, sleep-inducing
premedication.
S. Afr. Med. J., 47, 109 (1973).
The investigation of Ro 5-4200 (fiunitrazepam) as a pre-
medication before surgery was undertaken when, on com-
pletion of a pilot study, it was noted that Ro 5-4200 had
interesting possibilities. The drug seemed to work fast and
well. The patients slept soundly and there were minimal
side-effects. TO clinical evidence of interference with any
of the anaesthetic agents used was noted.
According to the manufacturers (Roche Products), Ro
5-4200 is a benzodiazepine derivative, possessing marked
sedative, muscle relaxant and spasmolytIc properties in
animal experiments. Tested extensively in animal ex-
periments, it had negligible effects on blood pressure and
very little effect on the ECG. The cardiac rate was slightly
reduced. High doses diminish the vasoconstrictor effect
of noradrenaline, histamine and acetylcholine in cats.
No measurable effect on respiration could be demonstrated.
The drug was well tolerated, and in normal doses did
not cause any changes in blood picture or blood chemistry
in animals or man.
MATERIALS AND MEmOD
The studies were done on patients seen in private anaes-
thetic practice.
Pilot Study
The drug was given to 30 patients at random the
night before surgery, and the sister on night duty was
asked to complete a form for each patient and note the
following details: (i) time elapsed until onset of sleep;
(ii) duration of sleep; (iii) depth of sleep; and (iv) tate.
at awakening.
The sister in charge was asked to assess the effectiveness
of the tablet. The patient was also asked the next morning
to assess the value of the tablet, and thirdly, the investi-
gator judged the results obtained by questioning the patient
and studying the information noted on the questionnaires
by the night sister.
The results obtained showed that Ro 5-4200 had a
very good hypnotic effect and it was then decided to
conduct a double-blind investigation (Tables I and Il).








Other minor operations ...
Double-blind study
Ro 5-4200
pilot study Ro 5-4200 Phenobarbital Placebo
39,7 years 44 years 34 years 38 years
(16 - 61 range) (22 - 78 range) (17 - 63 range) (19 - 70 range)
3 18 9 9
27 32 41 41
6 4 6 7
5 13 4 6
5 14 17 11
14 19 23 26
'Dale received: 26 July 1972.
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TABLE 11. RESPONSE TO THERAPY
Double-blind study
Ro 5-4200 Ro 5-4200 Phenobarbital Placebo
pilot study (50 patients) (50 patients) (50 patients)
Onset of sleep
20 minutes 15 (50%) 25 (50%) 12 7
- 45 minu:es 11 (36,6%) 21 (42%) 16 13
> 45 minutes 4 (13,3%) 4 ( 8%) 22 30
Duration of sleep
> 6 hours 25 (83,3%) 41 (82%) 23 20
4 - 6 hours 4 (13,3%) 5 (10%) 11 6
< 4 hours 1 ( 3,3%) 4 ( 8%) 16 21
Depth of sleep
Did not wake up 21 (70%) 26 (52%) 14 6
Woke up once 6 (20%) 11 (22%) 15 10
Woke up several times 3 (10%) 13 (26%) 21 29
State at awakening
Fresh 13 (43,3%) 30 (60%) 24 20
Tired 5 (16,6%) 10 (20%) 12 15
Drowsy 12 (40%) 10 (20%) 14 7
Investigator's rating
Excellent Not done 17 (34%) 5 2
Very good Not done 14 (28%) 11 3
Good Not done 12 (24%) 7 8
Moderate Not done 3 ( 6%) 12 6
Poor Not done 4 ( 8%) 15 31
Double-Blind Investigation
Sealed and invidually numbered packets containing
either Ro 5-4200 tablets (50 packets), or 100 mg phenobar-
bital tablets (50 packets), or placebo tablets (50 packets),
were issued on randomized basis to 150 patients the night
before surgery, noting the number of the tablet against
the name of the patient and the questionnaire. The contents
of the packet were unknown to the patient, sister or in-
vestigator. The latter was in possession of a sealed code
in case it was necessary to ascertain the identity of any
tablet at any time.
The sister was instructed to give the patient 1
Ma.ndrax tablet 2 hours after having received the trial
tablet, if the patient was still unable to sleep, and note
this on the case-history form. As in the pilot study, the
night sister was asked to fill in the cao;e-history form
for each patient. The mental state of each patient was
also clinically assessed by the investigator, e.g. nervousness,
tenseness, agitation, etc., and also whether the patient
was normally in the habit of taking sleeping tablets, other
drugs, alcohol, etc. The trial population of each therapy
group was comparable in every clinical parameter used
for this assessment.
The morning before surgery the patient was questioned
brieflY as to the effect of the tablet and the response
rated, in correlation with the completed details, as
excellent, very good, good, moderate or poor.
RESULTS
An analysis of the results clearly shows the excellent
response obtained with Ro 5-4200 in both the pilot
study and double-blind study, with 50 % of patients
asleep in less than 20 minutes, and well over 80 % in
less than 45 minutes. Over 80% of patients slept for more
than 6 hours. In the double-blind study 60% of patients
receiving Ro 5-4200 felt fresh on awakening, and 86%
of the patients slept very well (excellent, very good
or good) compared with a 46% response on phenobarbital,
and a 26% response on the placebo (Table II).
DISCUSSION
The results obtained from this investigation clearly
indicate that Ro 5-4200 has very definite therapeutic
value as a sleep-inducing agent. Results also clearly
demonstrated that patients on a placebo (42 %) and
phenobarbital (32%) slept poorly. Patients entering a
hospital for surgery definitely require a hypnotic the
night before surgery.'" One must recognize that the
majority of these patients are only temporary insomniacs,.
who, under normal circumstances, sleep without the help
of hypnotics, but who, under abnormal conditions such
as being in hospital, require therapeutic support
(transient insomnia).
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No serious side-effects were noted in any of the groups,
and Ro 5-4200 had no apparent effect on the anaesthetic
per se. About 20% of the patients on Ro 5-4200 were
drowsy on awakening, but no classical hangover were
noted.
Lastly, it will be noted that th.e trial population con-
sisted mostly of female patients. This can be explained
by the fact that patients receiving the tablets were mostly
on gynaecological operating lists.
I should like to thank Dr B. de Wet for his continued help
and advice, and also Roche Products (Pty) Limited, Isando,
for supplying the drugs. I would also like to thank the nursing
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to use Ro 5-4200 in this trial was obtained from the South
African Medicine Control Council.
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Yersinia enterocolitica in the Western Cape*
M. H. FThTLAYSON, N.A. COLDREY, B. STREET AND H. D. BREDE, Department of Medical
Microbiology, University of Stelienbosch and Tygerberg Hospital, Tiervlei, CP
SUMMARY
Yersinia enterocolitica, serotype 3, phage type 9a, has
been isolated for the first time in the Western Cape.
Sera from 59 abattoir workers were investigated for
the presence of 0 and H agglutinins. These were present
in one sample, suggesting a past infection.
Sera from 115 Nama-speaking adults of the Kuboes area
(Namaqualand), submitted to the same technique, gave 2
positive reactions. Eleven lepers with arthritis were
serologically negative.
S. A/r. Med. l., 47, 111 (1973).
A Pasteurella-like bacterium for many years was suspec-
ted as a cause of enteritis. This organism was shown by
Wouters,' Mollaret,' Graux and Mollaret; Winblad' and
others, to be the causal agent of cases of enteritis in
Belgium, the Netherlands and Scandinavia. In 1964 it was
correctly named Yersinia enterocolitica by Frederiksen.'
In South Africa the organism has been isolated from
man and pigs in Johannesburg and the Orange Free
State, by Rabson and Koornhof.' They grew 18 strains,
mostly from stools of patients, 11 of whom showed
symptoms of diarrhoea and vomiting. Two, however, were
isolated from asymptomatic food-handlers.
MATERIALS AND MEmODS
In the 2 cases reported here, the organisms were isolated
from stools of Coloured children suffering from diar-
-Date received: 13 September 1972.
rhoea, and admitted to the paediatric wards of the Karl
Bremer Hospital, Bellville, CP.
Faeces specimens were planted out on MacConkey.
medium (Oxoid), SS agar (Diteo) and selenite cystine
broth (Difco), to which novobiocin (40 mg per litre) was
added. This was used as an enrichment medium.
The first isolate was obtained from a subculture of the
enrichment medium after 5 days' incubation at 37·C. The
second isolation was made directly from inoculation of
MacConkey's medium after 48 hour~' incubation at 37"C.
After isolation cultures were tested for motility at 22°C
and 37°C, for biochemical reactions, antibiograms, and
for agglutinabiIity by self-prepared anti-Yersinia rabbit
sera. These were prepared from Yersinia strains supplied
by Professor S. Winblad.
BACTERIOLOGY
The two strains of Yersinia enterocolitica showed the.
typical morphological and cultural characteristics, in-
cluding motility at 22·C, but not at 37·C. Glucose, suc-
rose, and mannite were fermented; urease and catalase
were produced.
The organisms were methyl red-positive, and reduced
nitrates.
They were sensitive to the following drugs as tested,
using 6 mm sensitivity discs: ampicillin, streptomycin,
chloramphenicol, tetracyclines, erythromycin, kanamycin,
neomycin, furazolidone, cephalothin, and trimethoprimj
sulphamethoxazole, but resistant to novobiocin and peni:
ciIlin G.
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